Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina

Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0 Reklaitiene, 2012, Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983–2009, BMC Cardiovasc Disord, 12, 68, 10.1186/1471-2261-12-68 Mills, 2016, Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries, Circulation, 134, 441, 10.1161/CIRCULATIONAHA.115.018912 Pereira, 2009, Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries, J Hypertens, 27, 963, 10.1097/HJH.0b013e3283282f65 Merai, 2016, CDC grand rounds: a public health approach to detect and control hypertension, MMWR Morb Mortal Wkly Rep, 65, 1261, 10.15585/mmwr.mm6545a3 He, 2017, Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in Argentina: a randomized clinical trial, JAMA, 318, 1016, 10.1001/jama.2017.11358 Murray, 2003, Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 361, 717, 10.1016/S0140-6736(03)12655-4 Rubinstein, 2009, Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina, Cost Eff Resour Alloc, 7, 10, 10.1186/1478-7547-7-10 Mills, 2014, Comprehensive approach for hypertension control in low-income populations: rationale and study design for the hypertension control program in Argentina, Am J Med Sci, 348, 139, 10.1097/MAJ.0000000000000298 Drummond, 2015 Ramsey, 2015, Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good Research Practices Task Force Report, Value Health, 18, 161, 10.1016/j.jval.2015.02.001 2014 Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Sanchez, 2009, Latin American guidelines on hypertension. Latin American Expert Group, J Hypertens, 27, 905, 10.1097/HJH.0b013e32832aa6d2 Manca, 2005, Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility, Health Econ, 14, 487, 10.1002/hec.944 Rasanen, 2006, Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review, Int J Technol Assess Health Care, 22, 235, 10.1017/S0266462306051051 Augustovski, 2009, Argentine valuation of the EQ-5D health states, Value Health, 12, 587, 10.1111/j.1524-4733.2008.00468.x 2017, Informes Técnicos. Indice de Salarios.L Buenos Aires, Argentina, Indice de Salarios Grieve, 2005, Using multilevel models for assessing the variability of multinational resource use and cost data, Health Econ, 14, 185, 10.1002/hec.916 Ng, 2016, Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: an approach to model choice, Stat Methods Med Res, 25, 2036, 10.1177/0962280213511719 Hunger, 2012, Longitudinal beta regression models for analyzing health-related quality of life scores over time, BMC Med Res Methodol, 12, 144, 10.1186/1471-2288-12-144 Sachs, 2002, Macroeconomics and health: investing in health for economic development, Rev Panam Salud Pública, 12, 143, 10.1590/S1020-49892002000800017 Eichler, 2004, Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge?, Value Health, 7, 518, 10.1111/j.1524-4733.2004.75003.x Shillcutt, 2009, Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules, Pharmacoeconomics, 27, 903, 10.2165/10899580-000000000-00000 Woods, 2016, Country-level cost-effectiveness thresholds: initial estimates and the need for further research, Value Health, 19, 929, 10.1016/j.jval.2016.02.017 Glick, 2007 Briggs, 1997, Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation, Health Econ, 6, 327, 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W Nixon, 2010, Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared, Health Econ, 19, 316, 10.1002/hec.1477 Morisky, 1986, Concurrent and predictive validity of a self-reported measure of medication adherence, Med Care, 24, 67, 10.1097/00005650-198601000-00007 Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0 Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8 Gu, 2015, The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study, PLoS Med, 12, e1001860, 10.1371/journal.pmed.1001860 Steinberg, 2017, The DASH diet, 20 years later, JAMA, 317, 1529, 10.1001/jama.2017.1628 2010 Sanders, 2016, Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine, JAMA, 316, 1093, 10.1001/jama.2016.12195 Sculpher, 2006, Whither trial-based economic evaluation for health care decision making?, Health Econ, 15, 677, 10.1002/hec.1093